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n vivo infection of macrophages is a typical characteristic of lentiviral infections. Neurological complications, such as encephalitis, granulomatous interstitial pneumonia, and progressive dementia, are often associated with progression to AIDS during late-stage human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection (32) . Infected macrophages in the brain appear to be one of several factors that cause these AIDS-associated neuropathies (8, 22) . Furthermore, perivascular macrophages are the primary infected cell type in the brains of SIVmac239-infected rhesus macaques (47) .
Even though HIV type 1 (HIV-1) and SIVmac239 preferentially infect activated CD4 ϩ T cells (9, 10) , several studies have observed infected macrophages in HIV-1-infected patients and SIVmac239-, SIVmac251-, and SIV Delta B670 -infected rhesus macaques (12, 15, 18, 19, 30, 31, 35, 39, 44, 51) . Macrophages express the CD4 cell surface receptor, rendering them a potential target for these viruses (7, 15) . Using in situ hybridization, infected macrophages were observed in 10 of 21 lymph node biopsy specimens from the acute symptomatic stage and throughout the first year of infection in HIV-1-infected patients (39) . Infected macrophages comprised approximately 7% of the entire HIV-1-infected cell population in 10 lymph node samples containing HIV-1-infected macrophages (39) . Additionally, approximately 10% of the infected-cell population in endocervix and lymph node samples of acute SIVmac251-infected rhesus macaques expressed macrophage-specific lineage markers (51) . Furthermore, HIV-1-, SIVmac239-, SIVmac251-, and SHIV DH12R -infected macrophages were observed as early as 21 days postinfection and persisted for long periods of time (2, 11, 18, 19, 44, 47, 48) . Additionally, SHIV DH12R infection of rhesus macaques results in massive and irreversible depletion of CD4 ϩ T cells; however, high viral loads persist in several tissue compartments (18, 19) . In this model, macrophages were found to be the principal reservoir for SHIV and responsible for the high viral loads observed. Finally, macrophages are a persistent latent reservoir for HIV-1 (42) . Taken together, these studies suggest that macrophages play an important role in maintaining and enhancing HIV/SIV infection in vivo.
Because of the relatively small percentage of infected macrophages, the interaction between antigen-specific CD8 ϩ T cells and infected macrophages in HIV/SIV infection has been poorly studied. We, therefore, sought to determine whether SIV-specific CD8 ϩ T cells could control viral replication in infected macrophages.
Ex vivo tetramer-sorted SIV-specific CD8 ؉ T cells suppressed viral replication in SIV-infected CD4
؉ T cells. HIV/ SIV-specific CD8 ϩ T cells have been shown to suppress viral replication in HIV/SIV-infected CD4 ϩ T cells (26, 27, 36, 43, 45, 49, 50) . We confirmed that ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells could reduce viral replication in SIVinfected CD4 ϩ T cells in vitro. Ex vivo tetramer-sorted SIVspecific CD8 ϩ T cells (Table 1 ) from several progressor and elite controller (EC) animals (Table 2) were incubated with activated SIVmac239/316e-or SIVsmE660-infected CD4 ϩ T cells in viral suppression assays (45) . Ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells suppressed viral replication in SIVinfected major histocompatibility complex (MHC) class I-matched CD4 ϩ T cells (Fig. 1a) . This suppression was MHC class I dependent because the same ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells did not suppress viral replication in MHC class I-mismatched SIV-infected CD4 ϩ T cell targets (Fig. 1b) . Additionally, ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells effectively eliminated SIV-infected CD4 ϩ T cells (Fig. 1f) .
Most ex vivo tetramer-sorted SIV-specific CD8
؉ T cells cannot eliminate or suppress viral replication in SIV-infected macrophages. HIV/SIV-specific CD8 ϩ T cell lines and clones have been shown to eliminate HIV/SIV-infected macrophages (14, 38) . Indeed, HIV-specific CD8 ϩ T cell clones killed HIV-infected macrophages more efficiently than they killed HIV-infected CD4 ϩ T cells (14) . Additionally, GagCM9-specific CD8 ϩ T cells clones effectively eliminated SIVmac239/316e-infected macrophages in vitro (38) . Though CD8 ϩ T cell lines and clones can suppress viral replication in HIV-and SIV-infected macrophages, the suppressive properties of these cell lines and clones may not reflect the abilities of CD8 ϩ T cells in vivo. Cell lines and clones are maintained in tissue culture media containing interleukin-2 (IL-2) and are regularly restimulated, and selection for particular clonotypes can occur in vitro. We, therefore, sought to determine whether ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells could suppress viral replication in SIVmac239/316e-and SIVsmE660-infected macrophages. We reasoned that freshly sorted CD8 ϩ T cells might be more representative of the in vivo properties of CD8 ϩ T cells than in vitro cultured cell lines and clones. SIVmac239/316e encodes amino acid replacements in Env that facilitate macrophage infection in vitro. We also infected macrophages with SIVsmE660 because some of the animals were initially infected with SIVsmE660. We, therefore, infected monocyte-derived macrophages from naïve animals with either SIVmac239/316e or SIVsmE660. Most ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells that suppressed viral replication in SIVmac239/316e-infected CD4 ϩ T cells (Fig. 1a) failed to reduce viral replication in SIVmac239/316e-infected macrophages (Fig. 1c) . In fact, the average percent maximum suppression of viral replication in SIV-infected CD4 ϩ T cells was 60%, compared to 12% maximum suppression of viral replication in SIV-infected macrophages; the difference in the level of suppression observed between CD4 ϩ T cells and macrophages was statistically significant (P Ͻ 0.0001; Fig. 1e ). Some tetramer-sorted GagCM9-specific CD8 ϩ T cells suppressed viral replication in SIVmac239/316e-and SIVsmE660-infected macrophages (Fig. 1c) ; however, there was no correlation between suppression of viral replication in SIV-infected macrophages and the disease status or viral load of the animals ( Table 2 and Fig. 1c) or the purity to which the SIV-specific CD8 ϩ T cells were sorted (data not shown). There was no common distinguishing feature shared among the tetramer-sorted SIV-specific CD8 ϩ T cells that suppressed viral replication in SIV-infected macrophages nor among the animals from which these cells were derived. Additionally, tetramer-sorted CD8 ϩ T cells that suppressed viral replication in CD4 ϩ T cells most effectively were not always the tetramersorted SIV-specific CD8 ϩ T cells that suppressed viral replication in SIV-infected macrophages (Fig. 1a and c) . Suppression of viral replication that was observed in the few cases was MHC class I dependent because the same ex vivo tetramer-sorted SIV-specific CD8 ϩ T cells did not suppress viral replication in MHC class Imismatched SIVmac239/316e-infected macrophages (Fig. 1d) . Finally, ex vivo tetramer-sorted CD8 ϩ T cells restricted by both Mamu-A*01 and Mamu-B*08 failed to eliminate SIVmac239/ 316-infected macrophages (Fig. 1g) .
Our data suggest that macrophages may be an important reservoir for SIV because it may be difficult for SIV-specific CD8 ϩ T cells to suppress viral replication in this particular cell type.
Bulk CD8 ؉ T cells that suppress viral replication in SIV-infected CD4
؉ T cells poorly suppressed viral replication in SIVinfected macrophages. To extend our findings that freshly sorted SIV-specific CD8 ϩ T cells cannot efficiently suppress viral replication in SIV-infected macrophages, we next tested bulk CD8 ϩ T cells in the viral suppression assay as previously described (17, 28) . We isolated bulk CD8 ϩ T cells from ECs and naïve animals using an anti-CD8 antibody that recognizes a conformational epitope of the CD8␣␤ heterodimer, thereby excluding natural killer cells, which express only CD8␣ (40, 46) . Autologous CD4 ϩ T cells and macrophages were isolated, grown, and infected as described above. CD8 ϩ T cells were added to the infected targets at various concentrations and incubated for 3 days. CD8
ϩ T cells from ECs suppressed viral replication in autologous SIVmac239/316e-infected CD4 ϩ T cells (Fig. 2a) . However, at similar effector-totarget ratios, the same CD8 ϩ T cells were inefficient at suppressing viral replication in autologous SIVmac239/316e-infected macrophages (Fig. 2b) . CD8 ϩ T cells from SIV-naïve animals exerted some level of nonspecific suppression of viral replication in SIVinfected CD4 ϩ T cell targets only at the highest effector-to-target ratios; however, these levels rapidly decreased as the number of effectors was diluted. CD8 ϩ T cells from SIV-naïve animals could not suppress viral replication in SIV-infected macrophages at any effector-to-target ratio. 
FIG 1 Ex vivo tetramer-sorted SIV-specific CD8
ϩ T cells suppressed viral replication in SIV-infected CD4 ϩ T cells but were ineffective at suppressing viral replication in SIV-infected macrophages. We calculated the maximum percentage of viral suppression for each ex vivo tetramer-sorted SIV-specific CD8 ϩ T cell population using the number of viral RNA (vRNA) copies per milliliter of culture supernatant at 48 h with and without effector cells: (vRNA copies/ml without CD8 ϩ T cells Ϫ vRNA copies/ml with CD8 ϩ T cells)/vRNA copies/ml without CD8 ϩ T cells ϫ 100. We used only tetramer-sorted SIV-specific CD8 ϩ T cells that were greater than 50% specific as measured by postsort tetramer stains. The purity of the tetramer-sorted SIV-specific CD8 ϩ T cells did not correlate with their ability to suppress viral replication in SIV-infected CD4 ϩ T cells or macrophages. Experiments in panels a and c as well as panels b and d were directly matched:
HIV/SIV-specific CD8 ϩ T cells play an essential role in reducing peak and chronic-phase viral replication (3, 13, 20, 21, 23, 24, 29, 34, 41) . However, the SIV-specific CD8
ϩ T cells that we tested in this study did not appear to eliminate and suppress viral replication in SIV-infected macrophages. This does not mean that all CD8 ϩ T cells are incapable of suppressing viral replication in SIVinfected macrophages. For example, vaccine-induced CD8 ϩ T cells generated by certain vectors may be better than those generated by other vectors at suppressing viral replication in SIV-infected macrophages. Additionally, CD8 ϩ T cells from different stages of infection may have different abilities to suppress viral replication in macrophages. Unfortunately we did not have sufficient cell numbers to measure levels of expression markers, perforin, and granzyme to assess the "quality" of the CD8 ϩ T cells in our studies.
We previously observed differential abilities of SIV-specific CD8 ϩ T cells to suppress viral replication in SIV-infected CD4 ϩ T cells depending on the culturing method (5, 26, 27, 36, 45) . The culture conditions of CD8 ϩ T cell lines and clones may result in activated cell populations that have unusually high antiviral efficacy in vitro. Thus, these cultured cell populations may not reflect how CD8
ϩ T cells function in vivo. Though HIV and SIV preferentially infect activated CD4 ϩ T cells (9) , several studies have suggested that HIV and SIV can also infect macrophages in vivo (18, 31, 39, 51) . The importance of infected macrophages in vivo may, therefore, be underappreciated. Even with low numbers of infected macrophages in the total HIV/SIV-producing cellular compartment, macrophages may continually produce infectious virions and/or infect CD4 ϩ T cells in trans (4, 16, 42) . It is also possible that macrophages are relatively resistant to CD8 ϩ T cell-mediated lysis. Activated CD4 ϩ T cells produce virus 24 h after infection (45) when cell lysis begins (25, 33) . These infected cells are most susceptible to CD8 ϩ T cellmediated lysis during the first 12 h of this replicative cycle, before Nef downregulates MHC class I on the cell surface (1, 37). For macrophages, which can be long lived after infection (6, 42) , this CD8 ϩ T cell-mediated lytic window is likely also to be 12 h. However, if an infected macrophage is not lysed by CD8 ϩ T cells during this short window, the infected macrophage might continue producing virus for several months (42) . Thus, macrophages could targets were derived from the same animals on the same day, infected simultaneously the same way 4 days after harvesting, and incubated with the same tetramer-sorted effectors for 48 h. We used nonautologous targets because effector cells were harvested from SIV-infected animals and using autologous targets would not allow for an MHC class I-mismatch control. ϩ T cells from SIVmac239-infected ECs and SIV-naïve animals were incubated with SIVmac239/316e-infected autologous macrophages for 48 h at various concentrations. Dot plots were generated by gating on live, HLA-DR ϩ CD14 ϩ macrophages. We infected the CD4 ϩ T cells and macrophages to achieve similar intracellular Gag p27 levels at the end of the assay. CD4
ϩ T cells and macrophages from r96141 were approximately 25% infected, and CD4 ϩ T cells and macrophages from r04135 were approximately 16% infected. These data were representative of two independent experiments. actually be contributing significantly to viral production. Induction of HIV/SIV-specific CD8 ϩ T cells capable of killing infected macrophages or preventing establishment of the macrophage reservoir for HIV might be critical for controlling viral replication.
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